Meridian Bioscience gets FDA nod for C. difficile GDH test

12/28/2011 | American City Business Journals

The FDA has granted Meridian Bioscience clearance for its ImmunoCard test for glutamate dehydrogenase, a common Clostridium difficile antigen. Toxic C. difficile strains cause diarrhea and can result in death.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park